Picture of Azenta logo

AZTA — Azenta News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Azenta Q3 adjusted EPS beats estimates, revenue rises 12%

Azenta Q3 adjusted EPS beats estimates, revenue rises 12%


Overview

  • US life sciences solutions provider's fiscal Q3 revenue rose 12% yr/yr

  • Adjusted EPS for fiscal Q3 beat analyst expectations

  • Company repurchased $50 mln in shares under its buyback program


Outlook

  • Company expects FY26 reported revenue between $613 mln and $618 mln

  • Azenta expects FY26 adjusted EBITDA of $59 mln to $62 mln


Result Drivers

  • SEGMENT GROWTH - Higher revenue in Sample Management Solutions and Multiomics segments drove Q3 results

  • PRODUCT MIX - Sample Management Solutions growth was mainly driven by Sample Repository Solutions and Consumables and Instruments, partially offset by lower Automated Stores revenue

  • MARGIN PRESSURE - Gross margin declined due to unfavorable fixed-cost absorption from lower sales volumes and costs related to quality remediation and rework in Automated Stores


Company press release: ID:nPn7W22t1a


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Adjusted EPS

Beat

$0.16

$0.11 (6 Analysts)

Q3 Adjusted EBITDA

$18 mln

Q3 Adjusted EBITDA Margin

11.4%

Q3 Operating Income

-$4.18 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Azenta, Inc is $29.00, about 2.9% below its August 3 closing price of $29.88

  • The stock recently traded at 52 times the next 12-month earnings vs. a P/E of 26 three months ago


Reuters Recommended Reads

  • Aug 4 - Revvity raises annual profit, revenue forecasts on strong diagnostics demand

  • Aug 4 - Waters lifts annual forecasts on strong lab-equipment and diagnostics demand

  • Aug 4 - Bio-Rad Q2 revenue beats analyst estimates on clinical diagnostics growth


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Azenta

See all news